Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
about
Ovarian cancer stem cells: Can targeted therapy lead to improved progression-free survival?Optimized Stem Cell Detection Using the DyeCycle-Triggered Side Population Phenotype.Diverse involvement of EZH2 in cancer epigeneticsThe role of EZH2 in tumour progressionEZH2: not EZHY (easy) to deal.Cancer stem cell heterogeneity: origin and new perspectives on CSC targetingThe impact of novel retinoids in combination with platinum chemotherapy on ovarian cancer stem cells.Histones and their modifications in ovarian cancer - drivers of disease and therapeutic targets.Inhibition of KLF4 by Statins Reverses Adriamycin-Induced Metastasis and Cancer Stemness in Osteosarcoma CellsEpigenetics and pancreatic cancer: pathophysiology and novel treatment aspectsMetformin against cancer stem cells through the modulation of energy metabolism: special considerations on ovarian cancer.Role of EZH2 in cancer stem cells: from biological insight to a therapeutic target.Current limitations and future opportunities for epigenetic therapies.The side population of ovarian cancer cells defines a heterogeneous compartment exhibiting stem cell characteristicsLOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy.ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signatureNotch signaling in serous ovarian cancer.The PAX2-null immunophenotype defines multiple lineages with common expression signatures in benign and neoplastic oviductal epithelium.Stem cell-like gene expression in ovarian cancer predicts type II subtype and prognosisLiver x receptors protect from development of prostatic intra-epithelial neoplasia in mice.Pharmacologic down-regulation of EZH2 suppresses bladder cancer in vitro and in vivo.Cancer stem cell-like side population cells in clear cell renal cell carcinoma cell line 769P.Characterisation of human limbal side population cells isolated using an optimised protocol from an immortalised epithelial cell line and primary limbal cultures.Ovarian cancer stem cells: are they real and why are they important?Targeting specificity of dendritic cells on breast cancer stem cells: in vitro and in vivo evaluations.Ubiquitin B in cervical cancer: critical for the maintenance of cancer stem-like cell characters.Reversing paclitaxel resistance in ovarian cancer cells via inhibition of the ABCB1 expressing side population.EZH2 as a potential target in cancer therapy.Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes.ALDH1A1 is a novel EZH2 target gene in epithelial ovarian cancer identified by genome-wide approachesAn apoptosis-enhancing drug overcomes platinum resistance in a tumour-initiating subpopulation of ovarian cancer.Role of epigenetic modifications in luminal breast cancer.Drug Transporter-Mediated Protection of Cancer Stem Cells From Ionophore Antibiotics.Targeting the enhancer of zeste homologue 2 in medulloblastoma.Reversal of Chemoresistance in Ovarian Cancer by Co-Delivery of a P-Glycoprotein Inhibitor and Paclitaxel in a Liposomal Platform.Heterogeneity of Cancer Stem Cells: Rationale for Targeting the Stem Cell Niche.Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research.Critical role of Wnt/β-catenin signaling in driving epithelial ovarian cancer platinum resistance.Attributes of Oct4 in stem cell biology: perspectives on cancer stem cells of the ovary.
P2860
Q26826899-3C346639-9153-4243-9CB2-89525D795192Q27314826-86645A8A-7128-436A-A4A4-29D98E6E1657Q28084911-2C1128F9-C564-4956-8547-D548DF2E9E0EQ28255886-5C0E733B-FF46-4CD2-AB88-F27F8E7DCA06Q33610902-237133B6-3150-4533-B569-6A088C2E3112Q33649230-7458FFDF-FCB2-4D51-B938-5E89106A1E64Q33724839-55BD1969-9299-4643-8899-9909534A6075Q33741828-1D535489-171E-4616-94EB-03E5CCA2CABEQ33795254-60BF35F2-20BA-4277-B67E-4E8802AAFEA4Q33801377-ACE7EFAE-4378-417E-8C55-60D442F1679CQ33890763-05D72B09-FF4B-4826-ACF3-70D648BC86D3Q33914216-EC8F25EA-1FDF-4A15-AC04-B9E8AD1D3667Q34195077-B6E1DB1C-2310-4F5B-A3D0-02265A632A8AQ34334489-0AD6E7E9-EDD5-4BD4-81D4-E7678836DFE6Q34360216-6325D85D-3666-4DB7-B187-719FBE11171DQ34448718-47EC660E-4D3C-48C9-A339-A577616DF452Q34483574-33FA73DB-3691-4919-8C84-FA4CC12B8AA5Q34491211-913098C4-EBB3-4964-9D74-5FB18046B0E0Q34498581-51A4AFB8-D4FB-48F6-A63E-7DBEBFA28A77Q34639023-84A93B86-948F-43D3-8073-CB33D9C7C6B5Q34722551-4724E783-DE5D-4B58-8A6F-9C2C6E0D1239Q34786445-402BEADB-44D3-46F6-8938-493AF215E4EBQ34847829-6F757D17-E655-4207-B34F-A8F3500408DBQ35029291-4CF5AF10-BD5D-4FD8-A755-2F94BCD61956Q35047699-B3C14615-F76A-4147-BFB9-DA9C8558CAB1Q35063763-283AAAE5-063D-4456-9765-4646557BC292Q35075767-AE22C8B7-27BD-4751-BE20-42DE9FF214E8Q35200985-6402B603-929F-4D2E-9CBD-80A9C7C1437AQ35222823-B7B6C175-88BD-41F8-B269-0A3E59DB916EQ35727617-1167CDF8-3506-47C4-AAAB-8BB2ABBAB6C0Q35803467-452F4658-06B9-473A-A173-4766D530067AQ35941858-A097C093-53C3-4F26-8671-AD2C332F3467Q35963443-D87336BD-063C-4029-B395-A46C7FA36522Q35975423-51CA516E-E9D1-42FF-AD2B-B6B2EB06AAFDQ36032753-56656086-2FCF-4635-89F9-13C060B8FCEDQ36088140-7C7D6E45-34A7-4048-9B52-34EAEBDB62A5Q36165598-8A7E065D-CAD1-4524-B6EB-0139208CA3DDQ36358324-7C050B99-5D39-4FEE-BB57-31CFF637A29AQ36414274-7E8B7E20-2ADD-4E8B-8998-CD7634508E6BQ36507476-84A314CD-0367-463D-A8DC-6467F1274E64
P2860
Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Ovarian cancer stem cell-like ...... otherapy and overexpress EZH2.
@ast
Ovarian cancer stem cell-like ...... otherapy and overexpress EZH2.
@en
Ovarian cancer stem cell-like ...... otherapy and overexpress EZH2.
@nl
type
label
Ovarian cancer stem cell-like ...... otherapy and overexpress EZH2.
@ast
Ovarian cancer stem cell-like ...... otherapy and overexpress EZH2.
@en
Ovarian cancer stem cell-like ...... otherapy and overexpress EZH2.
@nl
prefLabel
Ovarian cancer stem cell-like ...... otherapy and overexpress EZH2.
@ast
Ovarian cancer stem cell-like ...... otherapy and overexpress EZH2.
@en
Ovarian cancer stem cell-like ...... otherapy and overexpress EZH2.
@nl
P2093
P2860
P1476
Ovarian cancer stem cell-like ...... motherapy and overexpress EZH2
@en
P2093
Alessandra Santos-Silva
Craig P Carden
Daniel Liber
David L Hudson
Ian Titley
Jenny M Hersey
Louisa Luk
Paul Mellor
Robert Brown
P2860
P304
P356
10.1158/1535-7163.MCT-10-0788
P50
P577
2011-01-07T00:00:00Z